Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.68 |
| ▸ | TPH1 | P17752 | 1/20 | 0.51 |
| ▸ | HPGDS | O60760 | 3/20 | 0.48 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12498477 | 0.93 | PIK3CA (0.68) | PIK3CATPH1PIK3R1MTORKMT2A | |
| SCHEMBL12498959 | 0.82 | PIK3CA (0.69) | PIK3CATPH1PIK3R1MTORKMT2A | |
| SCHEMBL1311223 | 0.81 | PIK3CA (0.77) | PIK3CATPH1MTORKMT2A | |
| SCHEMBL12499847 | 0.81 | PIK3CA (1.00) | PIK3CATPH1PIK3R1MTORKMT2A | |
| SCHEMBL15386457 | 0.81 | LMNA (0.46) | PIK3CATPH1KMT2A | |
| SCHEMBL12498761 | 0.80 | PIK3CA (0.67) | PIK3CAPIK3R1MTORKMT2A | |
| SCHEMBL12499236 | 0.80 | PIK3CA (0.64) | PIK3CATPH1PIK3R1MTORKMT2A | |
| SCHEMBL12498708 | 0.80 | PIK3CA (1.00) | PIK3CATPH1PIK3R1MTORKMT2A | |
| SCHEMBL15558168 | 0.79 | PIK3CA (0.58) | PIK3CAPIK3R1MTORKMT2APIK3CD | |
| SCHEMBL1311669 | 0.76 | PIK3CA (0.82) | PIK3CAPIK3R1MTORKMT2APIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | claimed |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2013-11-14 | — | — | US | claimed |
| WO-2012101654-A2 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-08-02 | — | — | WO | claimed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2013-11-14 | — | — | US | disclosed |
| WO-2012101654-A2 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | MTOR, MAPKAP1, PIK3R5 | PIK3CA 13/4885TPH1 1035/4885HPGDS 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.